Activities of Nicolae Vlad POPA related to 2008/0142(COD)
Plenary speeches (1)
Patients' rights in cross-border healthcare (debate)
Amendments (4)
Amendment 94 #
Proposal for a directive
Recital 12
Recital 12
(12) Given that it is impossible to know in advance whether a given healthcare provider will supply healthcare to a patient coming from another Member State or a patient from their own Member State, it is necessary that the requirements to ensure that healthcare is provided according to common principles and clear quality and safety standards are applicable to all type of healthcare in order to ensure the freedom to provide and obtain cross border healthcare which is the aim of the directive. Member States' authorities have to respect the shared overarching values of universality, access to good quality care, equity and solidarity, which have been already widely recognised by the Community institutions and by all the Member States as constituting a set of values that are shared by health systems across Europe. Members States also have to ensure that these values are respected with regard to patients and citizens from other Member States, and that all patients are treated equitably on the basis of their healthcare need rather than their Member State of social security affiliation. In doing so, Member States must respect the principles of freedom of movement of natural and legal persons within the internal market, non-discrimination inter alia with regard to nationality (or in the case of legal persons, with regard to the Member State in which they are established), necessity and proportionality of any restrictions on free movement. However, nothing in this Directive requires healthcare providers to accept for planned treatment or to prioritise patients from other Member States to the detriment of other patients with similar health needs, such as through increasing waiting time for treatment.
Amendment 172 #
Proposal for a directive
Recital 39 a (new)
Recital 39 a (new)
(39a) The decision to exceptionally authorise drugs which are not normally available in the Member State of affiliation should be made by a medical committee which will determine whether the patient's life is put at risk or the quality of his life is diminished, or if an alternative drug deemed to be similar could be provided.
Amendment 331 #
Proposal for a directive
Article 5 – paragraph 1 – point b and c
Article 5 – paragraph 1 – point b and c
(b) the application of such standards by healthcare providers in practice is regularly monitored and corrective action is taken when appropriate standards are not met, taking into account progresalthcare referred to in paragraph 1(a) is provided in accordance with standards and guidelines on quality and safety defined by the Member State of treatment ensuring that: (i) patients and healthcare providers from other Member States should be provided with information on such standards and guidelines, including provisions ion medical science and health technology; (c)supervision, inter alia by electronic means; (ii) patients and healthcare providers pfrovide all relevant information to enable patients to make an informed choice, in particularm other Member States should be provided with information on availability, prices and outcomes of the healthcare provided and details of their healthcare provider’s insurance cover or other means of personal or collective protection with regard to their professional liability;
Amendment 643 #
Proposal for a directive
Article 14 – paragraph 2 a (new)
Article 14 – paragraph 2 a (new)
2a. The decision to exceptionally authorise drugs which are not normally available in the Member State of affiliation should be made by a medical committee who will determine whether the patients life is put at risk or the quality of his life is diminished, or if an alternative drug could be provided deemed to be similar.